Product Name: AZD-9291 Mesylate ;Osimertinib Mesylate CAS NO:1421373-66-1
Chemical & Physical Properties
Appearance : Yellow Solid.
Assay : ≥99.5%
On November 13, 2015, the US FDA approved the listing of osimertinib oral tablet, a new drug of AstraZeneca in the UK, under the trade name of tagrisso. It is used for the treatment of advanced non-small cell lung cancer patients with chemical Book mutation of epidermal growth factor receptor (EGFR) T790M process or resistance to other EGFR inhibitors. It is necessary to detect whether T790M mutation occurs in patients with EGFR inhibitor osimoltinib before clinical use. Only patients with non-small cell lung cancer with T790M mutation can receive targeted treatment with ocimotinib.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.